Get notified when ALLO files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Removed Risk Disclosures

  • Material Weakness (removed) — Standalone paragraph on past material weakness removed; remediation language retained.
NASDAQ: ALLO Allogene Therapeutics, Inc. 10-Q

Allogene raises $200M, cash hits $388.9M; Q3 net loss widens to $50.4M

Filed November 6, 2026 · Period ending September 30, 2026 · Compared to 10-Q Nov 6, 2025 · ~1 min read

Key Changes

  • high

    April 2026 public offering raised $200.4M gross ($187.9M net) via 100.2M shares at $2.00; ATM sales added $20.7M net.

    Notes: April 2026 Public Offering verify on EDGAR →
  • high

    Cash and investments rose to $388.9M from $277.1M a year earlier, extending runway.

    Notes: Cash and investments view on EDGAR →
  • high

    Q3 net loss widened to $50.4M from $41.4M; nine-month loss narrowed to $135.7M from $152.1M.

    Notes: Segment net loss view on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (OWL 10-Q) is open in full — no account needed.

Partner

Trade ALLO commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Nov 9, 2026 · How we verify